Baker Bros. Advisors LP sold $1.1M of KALA
other at Kala Pharmaceuticals, Inc.. 730,408 shares at an average of $1.45, traded Sep 30, 2025, filed Oct 2, 2025.
Score components
- +8RoleOther
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -49.4%, 3m -63.9%, 6m -89.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-228536, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -21,376 | $1.60 | $34k | 97,120 | Oct 2, 2025 |
| Sep 30, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -195,425 | $1.60 | $312k | 887,973 | Oct 2, 2025 |
| Oct 1, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -50,640 | $1.38 | $70k | 46,480 | Oct 2, 2025 |
| Oct 1, 2025 | SOpen-market sale Common Stockindirect: See Footnotes | -462,967 | $1.38 | $641k | 425,006 | Oct 2, 2025 |
Related signals
Other insiders at Kala Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Kala Pharmaceuticals, Inc. | Todd Bazemore SEE REMARKS | $40k 47,768 shares | -57% | |
| 56Moderate | Kala Pharmaceuticals, Inc. | Romulus K Brazzell SEE REMARKS | $39k 46,748 shares | -57% | |
| 61Notable | Kala Pharmaceuticals, Inc. | Mark T Iwicki CHIEF EXECUTIVE OFFICER | $125k 154,894 shares | -60% | |
| 62Notable | Kala Pharmaceuticals, Inc. | Mary Reumuth CHIEF FINANCIAL OFFICER | $28k 33,197 shares | -53% | |
| 40Moderate | Kala Pharmaceuticals, Inc. | Darius Kharabi CHIEF BUSINESS OFFICER | $17k 20,806 shares | -33% | |
| 10Weak | Kala Pharmaceuticals, Inc. | Todd Bazemore SEE REMARKS | $16k 4,058 shares | -5% | |
| 10Weak | Kala Pharmaceuticals, Inc. | Romulus K Brazzell SEE REMARKS | $21k 5,251 shares | -6% | |
| 17Weak | Kala Pharmaceuticals, Inc. | Mark T Iwicki CHIEF EXECUTIVE OFFICER | $53k 13,227 shares | -5% | |
| 17Weak | Kala Pharmaceuticals, Inc. | Mary Reumuth CHIEF FINANCIAL OFFICER | $15k 3,631 shares | -6% | |
| 10Weak | Kala Pharmaceuticals, Inc. | Darius Kharabi CHIEF BUSINESS OFFICER | $18k 4,511 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.